Study Finds Different Types of Crystalloid Fluids Are Equally Effective for Pediatric Sepsis

Why It Matters

The findings remove uncertainty over which crystalloid to use, letting clinicians rely on the most readily available solution without compromising outcomes and simplifying sepsis protocols globally.

Key Takeaways

• Over 9,000 children enrolled across five countries in the trial
• MAKE30 rates: 3.4% balanced fluid vs 3.0% saline
• No mortality or hospital‑free day differences between fluid types
• Saline caused higher chloride; balanced fluid showed higher lactate levels
• Results support using any inexpensive crystalloid for pediatric septic shock

Pulse Analysis

Pediatric sepsis remains a leading cause of intensive care admission, affecting roughly 18,000 U.S. children annually and carrying a mortality risk of about 10%. While adult studies have suggested that balanced crystalloids may reduce complications compared with 0.9% saline, evidence in children has been sparse. The new trial, coordinated by the Pediatric Emergency Care Applied Research Network and partners across North America, Australia, New Zealand, and Costa Rica, fills that gap by enrolling a robust cohort that mirrors real‑world emergency department settings.

The investigators compared balanced solutions—designed to mimic plasma electrolyte composition—with standard 0.9% saline across more than 9,000 patients. The primary endpoint, major adverse kidney events at 30 days, differed minimally (3.4% vs 3.0%). Secondary outcomes, including mortality, length of stay and hospital‑free days, were indistinguishable, although biochemical profiles varied: saline recipients showed higher chloride levels, while balanced‑fluid patients had modestly elevated lactate. These data suggest that the choice of crystalloid can be driven by availability and cost rather than efficacy concerns, a reassuring message for resource‑limited settings.

Beyond immediate practice changes, the study underscores the power of large, multinational research networks to resolve long‑standing pediatric questions. While the overall results are neutral, the sheer size of the dataset enables future subgroup analyses that may uncover benefits for the sickest children. Guideline committees are likely to incorporate these findings, promoting flexibility in fluid resuscitation protocols and potentially accelerating the adoption of standardized sepsis pathways worldwide.